Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy
Launched by YANGZHOU UNIVERSITY · Sep 10, 2014
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
After successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. The baseline Doppler parameter will be recorded and the patient will be randomized into either interventional (warfarin) or control (aspirin) group. From postoperative day 3, patients in interventional (warfarin) group will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year, patients in control (aspirin) group will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year, and both groups will...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A clinical, radiological or histologic diagnosis of cirrhosis of any etiology
- • Splenomegaly with secondary hypersplenism, Platelet count \< 50\*10\^9/L
- • No evidence of PVT or spleno-mesenteric thrombosis by ultrasound evaluation and angio-CT
- • Informed consent to participate in the study
- Exclusion Criteria:
- • Hepatocellular carcinoma or any other malignancy
- • Hypercoagulable state other than the liver disease related
- • DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs
- • Base line INR \>2
- • Child-Pugh grade C
- • Recent peptic ulcer disease
- • History of Hemorrhagic stroke
- • Pregnancy
- • Uncontrolled Hypertension
- • Age\>75 yrs
- • F2 varices with red whale marks or F3 varices
- • Bleeding portal hypertension
- • Human immunodeficiency virus (HIV) infection
About Yangzhou University
Yangzhou University is a prestigious educational and research institution located in Yangzhou, China, dedicated to advancing knowledge and innovation in various fields, including medicine and healthcare. As a clinical trial sponsor, Yangzhou University leverages its extensive academic resources and expertise to conduct high-quality research aimed at improving patient outcomes and contributing to the scientific community. The university fosters collaboration among multidisciplinary teams and emphasizes ethical practices and regulatory compliance in its clinical research endeavors, ensuring the integrity and reliability of its findings. Through its commitment to excellence, Yangzhou University strives to enhance the understanding of health-related issues and develop effective interventions that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Yangzhou, Jiangsu, China
Patients applied
Trial Officials
Dou-Sheng Bai, MD
Study Chair
Clinical Medical College of Yangzhou University
Guo-Qing Jiang, MS
Study Director
Clinical Medical College of Yangzhou University
Ping Chen, MD
Principal Investigator
Clinical Medical College of Yangzhou University
Sheng-Jie Jin
Principal Investigator
Clinical Medical College of Yangzhou University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials